169 related articles for article (PubMed ID: 21062928)
1. Phase III clinical trial development: a process of chutes and ladders.
Dilts DM; Cheng SK; Crites JS; Sandler AB; Doroshow JH
Clin Cancer Res; 2010 Nov; 16(22):5381-9. PubMed ID: 21062928
[TBL] [Abstract][Full Text] [Related]
2. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.
Schroen AT; Petroni GR; Wang H; Thielen MJ; Sargent D; Benedetti JK; Cronin WM; Wickerham DL; Wang XF; Gray R; Cohn WF; Slingluff CL; Djulbegovic B
Clin Trials; 2011 Oct; 8(5):591-600. PubMed ID: 21878447
[TBL] [Abstract][Full Text] [Related]
3. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.
Cheng SK; Dietrich MS; Dilts DM
Clin Cancer Res; 2010 Nov; 16(22):5557-63. PubMed ID: 21062929
[TBL] [Abstract][Full Text] [Related]
4. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.
Abrams JS; Mooney MM; Zwiebel JA; Korn EL; Friedman SH; Finnigan SR; Schettino PR; Denicoff AM; Kruhm MG; Montello M; Misra RR; Ansher SS; DiPiazza KJ; Souhan EM; Wickerham DL; Giantonio BJ; O'Donnell RT; Sullivan DM; Soto NI; Fleming GF; Prindiville SA; Petryshyn RA; Hautala JA; Grad O; Zuckerman BL; Meyer RM; Yao JC; Baker LA; Buckner JC; Hortobagyi GN; Doroshow JH
J Natl Cancer Inst; 2013 Jul; 105(13):954-9. PubMed ID: 23776198
[TBL] [Abstract][Full Text] [Related]
5. Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.
Dilts DM; Sandler AB; Cheng SK; Crites JS; Ferranti LB; Wu AY; Finnigan S; Friedman S; Mooney M; Abrams J
J Clin Oncol; 2009 Apr; 27(11):1761-6. PubMed ID: 19255315
[TBL] [Abstract][Full Text] [Related]
6. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.
Korn EL; Freidlin B; Mooney M; Abrams JS
J Clin Oncol; 2010 Dec; 28(35):5197-201. PubMed ID: 21060029
[TBL] [Abstract][Full Text] [Related]
7. Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program.
Lyss AP; Lilenbaum RC
Clin Lung Cancer; 2009 Nov; 10(6):410-3. PubMed ID: 19900858
[TBL] [Abstract][Full Text] [Related]
8. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.
Dilts DM; Sandler AB; Baker M; Cheng SK; George SL; Karas KS; McGuire S; Menon GS; Reusch J; Sawyer D; Scoggins M; Wu A; Zhou K; Schilsky RL;
J Clin Oncol; 2006 Oct; 24(28):4553-7. PubMed ID: 17008694
[TBL] [Abstract][Full Text] [Related]
9. Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group.
Aplenc R; Fisher BT; Huang YS; Li Y; Alonzo TA; Gerbing RB; Hall M; Bertoch D; Keren R; Seif AE; Sung L; Adamson PC; Gamis A
Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2(Suppl 2):37-43. PubMed ID: 22552978
[TBL] [Abstract][Full Text] [Related]
10. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials.
Cheng SK; Dietrich MS; Dilts DM
Clin Cancer Res; 2011 Apr; 17(7):1947-55. PubMed ID: 21447723
[TBL] [Abstract][Full Text] [Related]
11. Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessment.
Zaren HA; Nair S; Go RS; Enos RA; Lanier KS; Thompson MA; Zhao J; Fleming DL; Leighton JC; Gribbin TE; Bryant DM; Carrigan A; Corpening JC; Csapo KA; Dimond EP; Ellison C; Gonzalez MM; Harr JL; Wilkinson K; Denicoff AM
J Oncol Pract; 2013 Mar; 9(2):e55-61. PubMed ID: 23814525
[TBL] [Abstract][Full Text] [Related]
12. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.
Schroen AT; Petroni GR; Wang H; Thielen MJ; Gray R; Benedetti J; Wang XF; Sargent DJ; Wickerham DL; Cronin W; Djulbegovic B; Slingluff CL
Clin Cancer Res; 2012 Jan; 18(1):256-62. PubMed ID: 21976533
[TBL] [Abstract][Full Text] [Related]
13. Sustainability and performance of the National Cancer Institute's Community Clinical Oncology Program.
Carpenter WR; Fortune-Greeley AK; Zullig LL; Lee SY; Weiner BJ
Contemp Clin Trials; 2012 Jan; 33(1):46-54. PubMed ID: 21986391
[TBL] [Abstract][Full Text] [Related]
14. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
15. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trial Metrics: The Complexity of Conducting Clinical Trials in North American Cancer Centers.
Lee C; Werner TL; Deal AM; Krise-Confair CJ; Bentz TA; Cummings TM; Grant SC; Lee AB; Moehle J; Moffett K; Peck H; Williamson S; Zafirovski A; Shaw K; Hofacker JK
JCO Oncol Pract; 2021 Jan; 17(1):e77-e93. PubMed ID: 33186085
[TBL] [Abstract][Full Text] [Related]
17. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
18. Enrollment of adolescent and young adult patients newly diagnosed with cancer in NCI CTEP-sponsored clinical trials before and after launch of the NCI National Clinical Trials Network.
Sankaran H; Finnigan SR; McShane LM; Best AF; Seibel NL
Cancer; 2022 Nov; 128(21):3843-3849. PubMed ID: 36089859
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of a Centralized Clinical Trials Coverage Analysis: A Joint Initiative of the American Society of Clinical Oncology and the National Cancer Institute.
Szczepanek CM; Hurley P; Good MJ; Denicoff A; Willenberg K; Dawson C; Kurbegov D
J Oncol Pract; 2017 Jun; 13(6):395-400. PubMed ID: 28481681
[TBL] [Abstract][Full Text] [Related]
20. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
Mantripragada KC; Olszewski AJ; Schumacher A; Perez K; Birnbaum A; Reagan JL; Mega A; Khurshid H; Bartley C; Lombardo A; Rossiter R; Papa A; Bakalarski P; Safran H
J Oncol Pract; 2016 Apr; 12(4):e396-404. PubMed ID: 26907448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
